Journal ArticleDOI
Clinical application of dynamic contrast enhanced ultrasound in monitoring the treatment response of chemoradiotherapy of pancreatic ductal adenocarcinoma.
TLDR
Depending on its unique advantages as non-radiation, effective and convenient, D-CEUS analysis and quantitative parameters, particularly MI, has potential application value in following up of the CRT treatment response in LAPC patients.Abstract:
OBJECTIVES To investigate the value of dynamic contrast enhanced ultrasound (D-CEUS) in monitoring the chemoradiotherapy (CRT) therapeutic response of local advanced pancreatic ductal adenocarcinoma (LAPC). PATIENTS AND METHODS From October 2017 to December 2018, 11 patients diagnosed as LAPC were included (7 men, 4 women; mean age: 61.1±8.6 years). The algorithm of CRT was as following: the radiotherapy dose was 50.4 Gy/28Fx with S-1 40 mg bid orally taken in radiotherapy day. Conventional ultrasound scan and CEUS were performed before and 4 weeks after CRT. All ultrasound examinations were performed by an ACUSON Oxana 2 ultrasound equipment (Siemens Medical Solutions, Germany) with a C 6-1 convex array transducer (1-6 MHz). Time intensity curves (TICs) were generated in the region of interests (ROIs) both in LAPC lesions and in its surrounding pancreas parenchyma by SonoLiver software (TOMTEC Imaging Systems). Quantitative perfusion parameters including maximum intensity (MI), rise time (RT), mean transit time (mTT) and time to peak (TTP) were analyzed and compared before and after CRT. RESULTS No significant difference could be found by conventional B mode ultrasound scan after CRT. TICs of CEUS showed lower ascending and descending slopes rate after CRT. Among all perfusion quantitative parameters, MI decreased significantly after CRT (42.1±18.8% vs 27.8±17.2%, P < 0.05). CONCLUSIONS Depending on its unique advantages as non-radiation, effective and convenient, D-CEUS analysis and quantitative parameters, particularly MI, has potential application value in following up of the CRT treatment response in LAPC patients.read more
Citations
More filters
Journal ArticleDOI
Monodisperse versus Polydisperse Ultrasound Contrast Agents: In Vivo Sensitivity and safety in Rat and Pig.
TL;DR: A first indication that monodisperse lipid-coated microbubbles formed by flow focusing are safe for in vivo use is given and may boost emerging applications of microbubble and ultrasound such as molecular imaging and therapy.
Journal ArticleDOI
Application of dynamic contrast enhanced ultrasound in distinguishing focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma.
TL;DR: DCE-US with quantitative analysis has the potential to make preoperative differential diagnosis between focal-type AIP and PDAC non-invasively.
Journal ArticleDOI
Contrast-enhanced ultrasound for evaluating response to pulsed-wave high-intensity focused ultrasound therapy in advanced pancreatic cancer.
TL;DR: CEUS can evaluating response to PW-HIFU in advanced pancreatic cancer and Quantitative analysis may help to assess the short-term efficacy of patients and help for individualized treatment.
Journal ArticleDOI
Application of Dynamic Contrast-Enhanced MRI in the Diagnosis of Rheumatoid Arthritis
TL;DR: The correlation between hemodynamic parameters and omeractramris score, clinical laboratory indexes, and activity score (DAS28), analyzes its feasibility in evaluating the prognosis of RA, and provides a reliable basis for the rational formulation of an early RA treatment plan.
Journal ArticleDOI
Prediction of Pathological Grades of Pancreatic Neuroendocrine Tumors Based on Dynamic Contrast-Enhanced Ultrasound Quantitative Analysis
Daohui Yang,Juan Cheng,Xiaofan Tian,Qi Zhang,Lingyun Yu,Yijie Qiu,Xiu-Yun Lu,Wenhui Lou,Yi Dong,Wenping Wang +9 more
TL;DR: Wang et al. as discussed by the authors investigated whether dynamic contrastenhanced ultrasound (DCE-US) analysis and quantitative parameters could be helpful for predicting histopathologic grades of pancreatic neuroendocrine tumors (pNETs).
References
More filters
Journal ArticleDOI
Cancer statistics, 2016
TL;DR: Overall cancer incidence trends are stable in women, but declining by 3.1% per year in men, much of which is because of recent rapid declines in prostate cancer diagnoses, and brain cancer has surpassed leukemia as the leading cause of cancer death among children and adolescents.
Journal ArticleDOI
Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.
Michel Claudon,Christoph F. Dietrich,Byung Ihn Choi,David O. Cosgrove,Masatoshi Kudo,Christian Pállson Nolsøe,Fabio Piscaglia,Stephanie R. Wilson,Richard G. Barr,Maria Cristina Chammas,Nitin Chaubal,Min-hua Chen,Dirk-André Clevert,Jean Michel Correas,Hong Ding,Flemming Forsberg,J. Brian Fowlkes,Robert N Gibson,Barry B. Goldberg,Nathalie Lassau,Edward Leen,Robert F. Mattrey,Fuminori Moriyasu,Luigi Solbiati,Hans Peter Weskott,Hui-Xiong Xu +25 more
TL;DR: These liver CEUS guidelines and recommendations are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis and improve the management of patients worldwide.
Journal ArticleDOI
Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology
Margaret A. Tempero,Mokenge P. Malafa,Mahmoud M. Al-Hawary,Horacio J. Asbun,Andrew Bain,Stephen W. Behrman,Al B. Benson,Ellen F. Binder,Dana Backlund Cardin,Charles Cha,E. Gabriela Chiorean,Vincent Chung,Brian G. Czito,Mary Dillhoff,Efrat Dotan,Cristina R. Ferrone,Jeffrey M. Hardacre,William G. Hawkins,Joseph M. Herman,Andrew H. Ko,Srinadh Komanduri,Albert C. Koong,Noelle K. LoConte,Andrew M. Lowy,Cassadie Moravek,Eric K. Nakakura,Eileen M. O'Reilly,Jorge Obando,Sushanth Reddy,Courtney L. Scaife,Sarah P. Thayer,Colin D. Weekes,Robert A. Wolff,Brian M. Wolpin,Jennifer L. Burns,Susan Darlow +35 more
TL;DR: The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection, as well as on management of locally advanced unresectable and metastatic disease.
Journal ArticleDOI
The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version)
Paul S. Sidhu,Vito Cantisani,Christoph F. Dietrich,Odd Helge Gilja,Adrian Saftoiu,Eva Bartels,Michele Bertolotto,Fabrizio Calliada,Dirk-André Clevert,David O. Cosgrove,Annamaria Deganello,Mirko D'Onofrio,Francesco Maria Drudi,Simon Freeman,Chris J Harvey,Christian Jenssen,Ernst Michael Jung,Andrea Klauser,Nathalie Lassau,Maria Franca Meloni,Edward Leen,Carlos Nicolau,Christian Pállson Nolsøe,Fabio Piscaglia,Francesco Prada,H. Prosch,Maija Radzina,Luca Savelli,Hans Peter Weskott,Hessel Wijkstra +29 more
TL;DR: The updated version of the EFSUMB guidelines on the application of non-hepatic contrast-enhanced ultrasound (CEUS) deals with the use of microbubble ultrasound contrast outside the liver in the many established and emerging applications.
Journal ArticleDOI
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal
TL;DR: Serum CA 19-9 serum levels can provide important information with regards to prognosis, overall survival, and response to chemotherapy as well as predict post-operative recurrence, but non-specific expression in several benign and malignant diseases, false negative results in Lewis negative genotype and an increased false positive results in the presence of obstructive jaundice severely limit the universal applicability of serum CA 19,9 levels in pancreatic cancer management.